Trial Outcomes & Findings for A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis (NCT NCT00089791)
NCT ID: NCT00089791
Last Updated: 2022-11-08
Results Overview
A new vertebral fracture, assessed by lateral spine X-ray using Genant semiquantitative scoring method, was identified as an ≥ 1 grade increase from the Baseline grade of 0 in any vertebra from T4 to L4. New vertebral fractures included morphometric vertebral fractures (assessed at scheduled visits and not associated with signs or symptoms \[or both\] indicative of a fracture) and clinical vertebral fractures (assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms indicative of a fracture, excluding any fracture associated with high trauma severity or a pathologic fracture).
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
7808 participants
Primary outcome timeframe
36 months
Results posted on
2022-11-08
Participant Flow
First Subject Enrolled: 03-Aug-2004 Last Subject Enrolled: 01-Jun-2005
Participant milestones
| Measure |
Placebo
Placebo administered subcutaneously once every 6 months for 3 years.
|
Denosumab 60 mg Q6M
Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
|
|---|---|---|
|
Overall Study
STARTED
|
3906
|
3902
|
|
Overall Study
Received Study Medication
|
3883
|
3879
|
|
Overall Study
Safety Analysis Set
|
3876
|
3886
|
|
Overall Study
COMPLETED
|
3206
|
3272
|
|
Overall Study
NOT COMPLETED
|
700
|
630
|
Reasons for withdrawal
| Measure |
Placebo
Placebo administered subcutaneously once every 6 months for 3 years.
|
Denosumab 60 mg Q6M
Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
|
|---|---|---|
|
Overall Study
Physician Decision
|
6
|
3
|
|
Overall Study
Adverse Event
|
81
|
93
|
|
Overall Study
Withdrawal by Subject
|
403
|
344
|
|
Overall Study
Death
|
78
|
62
|
|
Overall Study
Disease progression
|
7
|
3
|
|
Overall Study
Ineligibility determined
|
12
|
9
|
|
Overall Study
Lost to Follow-up
|
57
|
57
|
|
Overall Study
Noncompliance
|
17
|
13
|
|
Overall Study
Other
|
20
|
32
|
|
Overall Study
Protocol deviation
|
12
|
10
|
|
Overall Study
Requirement for alternative therapy
|
7
|
4
|
Baseline Characteristics
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
Baseline characteristics by cohort
| Measure |
Placebo
n=3906 Participants
Placebo administered subcutaneously once every 6 months for 3 years.
|
Denosumab 60 mg Q6M
n=3902 Participants
Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
|
Total
n=7808 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
72.3 Years
STANDARD_DEVIATION 5.2 • n=99 Participants
|
72.3 Years
STANDARD_DEVIATION 5.2 • n=107 Participants
|
72.3 Years
STANDARD_DEVIATION 5.2 • n=206 Participants
|
|
Sex: Female, Male
Female
|
3906 Participants
n=99 Participants
|
3902 Participants
n=107 Participants
|
7808 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
White or Caucasian
|
3629 Participants
n=99 Participants
|
3609 Participants
n=107 Participants
|
7238 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
27 Participants
n=99 Participants
|
30 Participants
n=107 Participants
|
57 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Hispanic or Latino
|
232 Participants
n=99 Participants
|
241 Participants
n=107 Participants
|
473 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Asian
|
8 Participants
n=99 Participants
|
9 Participants
n=107 Participants
|
17 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Japanese
|
4 Participants
n=99 Participants
|
7 Participants
n=107 Participants
|
11 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
|
2 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
|
Race/Ethnicity, Customized
Other
|
4 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
10 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: 36 monthsPopulation: Primary Efficacy Analysis Set, which includes all randomized participants who have a baseline and ≥ 1 postbaseline evaluation of vertebral fracture at or before 3 years. Last Observation Carried Forward was used.
A new vertebral fracture, assessed by lateral spine X-ray using Genant semiquantitative scoring method, was identified as an ≥ 1 grade increase from the Baseline grade of 0 in any vertebra from T4 to L4. New vertebral fractures included morphometric vertebral fractures (assessed at scheduled visits and not associated with signs or symptoms \[or both\] indicative of a fracture) and clinical vertebral fractures (assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms indicative of a fracture, excluding any fracture associated with high trauma severity or a pathologic fracture).
Outcome measures
| Measure |
Placebo
n=3691 Participants
Placebo administered subcutaneously once every 6 months for 3 years.
|
Denosumab 60 mg Q6M
n=3702 Participants
Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
|
|---|---|---|
|
Number of Participants With New Vertebral Fractures
|
264 Participants
|
86 Participants
|
SECONDARY outcome
Timeframe: 36 monthsPopulation: Full analysis set (all randomized participants)
Nonvertebral fractures (osteoporotic) were those occurring on study excluding those of the vertebrae (cervical, thoracic, and lumbar), skull, facial, mandible, metacarpus, finger phalanges, and toe phalanges. Fractures associated with high trauma severity (fractures that were the result of a fall from higher than the height of a stool, chair, first rung on a ladder or equivalent (\> 20 inches) or was the result of severe trauma other than a fall) and pathologic fractures were excluded from this category. Nonvertebral fractures were required to be confirmed either by radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging (MRI), or by documentation in a radiology report, surgical report, or discharge summary.
Outcome measures
| Measure |
Placebo
n=3906 Participants
Placebo administered subcutaneously once every 6 months for 3 years.
|
Denosumab 60 mg Q6M
n=3902 Participants
Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
|
|---|---|---|
|
Number of Participants With Nonvertebral Fractures
|
293 Participants
|
238 Participants
|
SECONDARY outcome
Timeframe: 36 monthsPopulation: Full analysis set
Hip fractures are a subset of nonvertebral fractures including femur neck, femur intertrochanter, and femur subtrochanter.
Outcome measures
| Measure |
Placebo
n=3906 Participants
Placebo administered subcutaneously once every 6 months for 3 years.
|
Denosumab 60 mg Q6M
n=3902 Participants
Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
|
|---|---|---|
|
Number of Participants With a Hip Fracture
|
43 Participants
|
26 Participants
|
Adverse Events
Placebo
Serious events: 972 serious events
Other events: 3107 other events
Deaths: 0 deaths
Denosumab 60 mg Q6M
Serious events: 1004 serious events
Other events: 3073 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Placebo
n=3876 participants at risk
Placebo administered subcutaneously once every 6 months for 3 years.
|
Denosumab 60 mg Q6M
n=3886 participants at risk
Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
|
|---|---|---|
|
Musculoskeletal and connective tissue disorders
Morphoea
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Agranulocytosis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.26%
10/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.28%
11/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Anaemia megaloblastic
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Anaemia of chronic disease
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Anaemia vitamin B12 deficiency
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Coagulopathy
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Haemorrhagic anaemia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Idiopathic thrombocytopenic purpura
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.15%
6/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Normochromic normocytic anaemia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Pancytopenia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Pernicious anaemia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Thrombocythaemia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Acute coronary syndrome
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.31%
12/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Angina pectoris
|
0.46%
18/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.85%
33/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Angina unstable
|
0.31%
12/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.28%
11/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Aortic valve disease
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Aortic valve disease mixed
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Aortic valve incompetence
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Aortic valve stenosis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Arrhythmia
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Arteriosclerosis coronary artery
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Atrial fibrillation
|
0.85%
33/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.93%
36/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Atrial flutter
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Atrial tachycardia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Atrioventricular block
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Atrioventricular block complete
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Atrioventricular block second degree
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Bradyarrhythmia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Bradycardia
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Bundle branch block left
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Bundle branch block right
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Cardiac arrest
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Cardiac failure
|
0.39%
15/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.41%
16/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Cardiac failure acute
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Cardiac failure chronic
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.34%
13/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.26%
10/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Cardiac tamponade
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Cardio-respiratory arrest
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Cardiogenic shock
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Cardiomegaly
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Cardiomyopathy
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Cardiopulmonary failure
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Congestive cardiomyopathy
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Coronary artery disease
|
0.44%
17/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.39%
15/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Coronary artery insufficiency
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Coronary artery occlusion
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Coronary artery stenosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Coronary artery thrombosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Heart valve calcification
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Heart valve incompetence
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Hypertensive cardiomyopathy
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Hypertensive heart disease
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Intracardiac thrombus
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Ischaemic cardiomyopathy
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Left ventricular failure
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Left ventricular hypertrophy
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Mitral valve disease
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Myocardial infarction
|
0.59%
23/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.64%
25/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.31%
12/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Palpitations
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Pericardial haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Sick sinus syndrome
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.23%
9/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Sinus arrhythmia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Sinus bradycardia
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Supraventricular extrasystoles
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.18%
7/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Tachyarrhythmia
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Tachycardia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Tachycardia paroxysmal
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Ventricle rupture
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Ventricular fibrillation
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Ventricular tachycardia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Cardiac disorders
Wolff-Parkinson-White syndrome
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Congenital, familial and genetic disorders
Corneal dystrophy
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Acute vestibular syndrome
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Deafness bilateral
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Deafness unilateral
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Hearing impaired
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Inner ear disorder
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Meniere's disease
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Tympanic membrane perforation
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Vertigo
|
0.26%
10/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.41%
16/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Vertigo positional
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Vestibular disorder
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Ear and labyrinth disorders
Vestibular neuronitis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Endocrine disorders
Goitre
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Endocrine disorders
Hyperparathyroidism
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Endocrine disorders
Hypothyroidism
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Endocrine disorders
Toxic nodular goitre
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Angle closure glaucoma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Cataract
|
0.72%
28/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.54%
21/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Choroidal haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Corneal decompensation
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Dacryostenosis acquired
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Entropion
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Eye haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Glaucoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Keratitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Lens dislocation
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Macular degeneration
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Macular hole
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Myopia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Optic ischaemic neuropathy
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Retinal detachment
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Retinal disorder
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Retinal haemorrhage
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Retinal tear
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Retinal vascular thrombosis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Retinal vein thrombosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Vision blurred
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Visual acuity reduced
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Visual disturbance
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Eye disorders
Vitreous haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Abdominal adhesions
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.15%
6/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.21%
8/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Abdominal strangulated hernia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Acute abdomen
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Anal fissure
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Anal fistula
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Anal haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Anal polyp
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Anal ulcer
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Appendicitis perforated
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Barrett's oesophagus
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Change of bowel habit
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Colitis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Colitis ischaemic
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Colitis ulcerative
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Colonic haematoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Colonic obstruction
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Colonic polyp
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Colonic pseudo-obstruction
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Colonic stenosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Constipation
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.21%
8/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Diverticular perforation
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Diverticulitis intestinal haemorrhagic
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Diverticulum
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.18%
7/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.21%
8/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Duodenal ulcer
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Duodenal ulcer haemorrhage
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Duodenal ulcer perforation
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Duodenitis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Dysphagia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Enterocele
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Erosive oesophagitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Faecaloma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Gastric haemorrhage
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Gastric perforation
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Gastric ulcer haemorrhage
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Gastritis
|
0.15%
6/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.23%
9/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.15%
6/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Gastrooesophageal sphincter insufficiency
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Haematemesis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Haematochezia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Ileus
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.18%
7/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Inguinal hernia strangulated
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Inguinal hernia, obstructive
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Intestinal cyst
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Intestinal haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Intestinal ischaemia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Intestinal perforation
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Intussusception
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Large intestinal haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Mallory-Weiss syndrome
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Mechanical ileus
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Melaena
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Mesenteric artery embolism
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Nausea
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Pancreatic cyst
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Pancreatic disorder
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Pancreatic fistula
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Pancreatic pseudocyst
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Pancreatitis chronic
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Peritoneal haematoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Peritonitis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Pharyngoesophageal diverticulum
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Rectal prolapse
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Reflux gastritis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Retroperitoneal haemorrhage
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Salivary gland cyst
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Sigmoiditis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Small intestinal perforation
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Subileus
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Umbilical hernia
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Volvulus
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Vomiting
|
0.15%
6/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Accidental death
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Asthenia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Cardiac death
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Chest discomfort
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Chest pain
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Chills
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Cyst
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Death
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Fatigue
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Feeling hot
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Gait disturbance
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
General physical health deterioration
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Generalised oedema
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Hernia obstructive
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Impaired healing
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Inflammation
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Malaise
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Multi-organ failure
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Non-cardiac chest pain
|
0.23%
9/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.26%
10/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Oedema peripheral
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Pain
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Pelvic mass
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Polyp
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Pseudocyst
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Pyrexia
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Sensation of pressure
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Sudden death
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
General disorders
Ulcer haemorrhage
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Bile duct obstruction
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Bile duct stone
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Biliary colic
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Biliary tract disorder
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Cholangitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Cholangitis acute
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Cholecystitis chronic
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.44%
17/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.44%
17/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Cholelithiasis obstructive
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Cholestasis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Chronic hepatitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Gallbladder polyp
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Hepatic cirrhosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Hepatic mass
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Hepatitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Hepatocellular injury
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Hydrocholecystis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Jaundice
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Liver disorder
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Hepatobiliary disorders
Post cholecystectomy syndrome
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Immune system disorders
Anaphylactic shock
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Abdominal abscess
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Abscess intestinal
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Acrodermatitis chronica atrophicans
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Anal abscess
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Appendiceal abscess
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Appendicitis
|
0.18%
7/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.18%
7/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Arthritis viral
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Aspergillosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Bacteraemia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Bacterial pyelonephritis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Biliary tract infection fungal
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Borrelia infection
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Bronchiectasis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Bronchitis
|
0.18%
7/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Bronchopneumonia
|
0.18%
7/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Cellulitis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Cervicitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Cholecystitis infective
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Chronic sinusitis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Clostridium difficile colitis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Cystitis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Diverticulitis
|
0.15%
6/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.21%
8/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Encephalitis viral
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Endocarditis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Endocarditis bacterial
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Erysipelas
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.18%
7/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Escherichia infection
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Gangrene
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Gastric infection
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Gastroenteritis
|
0.18%
7/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.23%
9/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Gastroenteritis Escherichia coli
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Gastroenteritis bacterial
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Gastroenteritis rotavirus
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Gastrointestinal infection
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Helicobacter infection
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Herpes zoster
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Herpes zoster ophthalmic
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Infected cyst
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Infected skin ulcer
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Infective exacerbation of chronic obstructive airways disease
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Influenza
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Intervertebral discitis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Kidney infection
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Labyrinthitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Liver abscess
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Lobar pneumonia
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Localised infection
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Lung abscess
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Lung infection
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Lung infection pseudomonal
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Lyme disease
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Lymphangitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Meningitis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Otitis media
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Paronychia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Peridiverticular abscess
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Peritoneal abscess
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Phlebitis infective
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pleural infection
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pneumonia
|
0.93%
36/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.87%
34/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pneumonia bacterial
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pneumonia pneumococcal
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pneumonia viral
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Post procedural infection
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Post procedural pneumonia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pseudomonas infection
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pulmonary tuberculosis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pyelonephritis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pyelonephritis acute
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pyelonephritis chronic
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pyometra
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Pyothorax
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Renal abscess
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Respiratory tract infection
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Respiratory tract infection fungal
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Salmonellosis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Sepsis
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Septic shock
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Sinusitis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Skin bacterial infection
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Staphylococcal infection
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Staphylococcal sepsis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Subcutaneous abscess
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Tuberculosis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Tubo-ovarian abscess
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Typhus
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Urinary tract infection
|
0.26%
10/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.41%
16/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Urosepsis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Vaginal infection
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Viral infection
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Wound infection
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Accident
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Accidental overdose
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Anaemia postoperative
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Anastomotic ulcer haemorrhage
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Animal bite
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Brain herniation
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Cardiac pacemaker malfunction
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Cardiac valve replacement complication
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Cartilage injury
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Cervical vertebral fracture
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Chemical eye injury
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Clavicle fracture
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Concussion
|
0.28%
11/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.18%
7/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Delayed recovery from anaesthesia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Device malfunction
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Drug toxicity
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Excoriation
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Eye injury
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Facial bones fracture
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Failure of implant
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Fall
|
0.46%
18/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.41%
16/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Femoral neck fracture
|
0.52%
20/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.33%
13/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.72%
28/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.36%
14/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Fibula fracture
|
0.26%
10/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.18%
7/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Fractured ischium
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Fractured sacrum
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Head injury
|
0.23%
9/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.34%
13/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.28%
11/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Ilium fracture
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Incisional hernia
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Injury
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Joint sprain
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Limb crushing injury
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Lumbar vertebral fracture
|
0.23%
9/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Medical device complication
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Meniscus lesion
|
0.18%
7/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Multiple injuries
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Muscle rupture
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Overdose
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Patella fracture
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.15%
6/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Periorbital haematoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Pneumothorax traumatic
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Poisoning
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Post procedural complication
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Postoperative constipation
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Postoperative hernia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Postoperative ileus
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Postoperative wound complication
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Postpericardiotomy syndrome
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.59%
23/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.64%
25/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Retinal injury
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Sciatic nerve injury
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Skeletal injury
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Skull fracture
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Splenic injury
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Splenic rupture
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Sternal fracture
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Therapeutic agent toxicity
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Thoracic vertebral fracture
|
0.23%
9/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
0.26%
10/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Traumatic brain injury
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Ulna fracture
|
0.44%
17/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.18%
7/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Vascular graft complication
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Wound
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Wound dehiscence
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Investigations
Blood potassium decreased
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Investigations
Blood pressure increased
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Investigations
Body temperature increased
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Investigations
Cardiac murmur
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Investigations
Heart rate irregular
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Investigations
Hepatic enzyme
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Investigations
Hepatic enzyme increased
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Investigations
Intraocular pressure increased
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Investigations
Liver function test abnormal
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Investigations
Weight decreased
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Anorexia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.18%
7/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.18%
7/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Electrolyte imbalance
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Gout
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.26%
10/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.39%
15/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Arthropathy
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.52%
20/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.51%
20/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Bone callus excessive
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Bunion
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Cervical spinal stenosis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Chondritis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Chondromalacia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Collagen disorder
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Connective tissue disorder
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Costochondritis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Dupuytren's contracture
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Extraskeletal ossification
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Foot deformity
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Fracture malunion
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc disorder
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.39%
15/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Joint stiffness
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Mobility decreased
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Myositis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Osteitis deformans
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
2.0%
79/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
1.6%
63/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Osteochondrosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Periarthritis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Polymyalgia rheumatica
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Resorption bone increased
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Scoliosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Sjogren's syndrome
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Spinal column stenosis
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Spinal disorder
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Spinal osteoarthritis
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.26%
10/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Spondylitis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Spondylolisthesis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Sympathetic posterior cervical syndrome
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Synovial cyst
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Tenosynovitis stenosans
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Abdominal neoplasm
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acral lentiginous melanoma stage unspecified
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenoma benign
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adrenal adenoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.18%
7/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign laryngeal neoplasm
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of eye
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of thyroid gland
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign ovarian tumour
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign soft tissue neoplasm
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer recurrent
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder neoplasm
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone neoplasm malignant
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain neoplasm
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain neoplasm malignant
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.64%
25/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.87%
34/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer metastatic
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchial carcinoma
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the stomach
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cerebellar tumour
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma stage 0
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholesteatoma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon adenoma
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.21%
8/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.28%
11/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer metastatic
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon neoplasm
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma recurrent
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Essential thrombocythaemia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer metastatic
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gammopathy
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.18%
7/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal carcinoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma multiforme
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic neoplasm
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic neoplasm malignant
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal adenocarcinoma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Keratoacanthoma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna stage unspecified
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma metastatic
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung cancer metastatic
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.23%
9/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.23%
9/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage unspecified
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymph node cancer metastatic
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant lymphoid neoplasm
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma in situ
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm progression
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mesothelioma malignant
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to abdominal cavity
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to adrenals
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone marrow
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to fallopian tube
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to large intestine
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to liver
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lung
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lymph nodes
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pleura
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to spine
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic bronchial carcinoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic malignant melanoma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic neoplasm
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Multiple myeloma
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelodysplastic syndrome
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasal cavity cancer
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm malignant
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer metastatic
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian adenoma
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer metastatic
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian fibroma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian neoplasm
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma metastatic
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papillary thyroid cancer
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroid tumour benign
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer stage unspecified
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary tumour benign
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasmacytoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pseudolymphoma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer stage III
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal oncocytoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Schloffer tumour
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin cancer
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin papilloma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer metastatic
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Teratoma
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid adenoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid neoplasm
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral cancer recurrent
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine cancer
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyoma
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyosarcoma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Amnesia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Amyotrophic lateral sclerosis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Aphasia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Balance disorder
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Brain stem infarction
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Brain stem ischaemia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Carotid artery stenosis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Carpal tunnel syndrome
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cauda equina syndrome
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebellar infarction
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebellar syndrome
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebral arteriosclerosis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebral artery embolism
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebral artery stenosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebral circulatory failure
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebral infarction
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebral ischaemia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebral thrombosis
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.59%
23/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.82%
32/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebrovascular disorder
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cerebrovascular insufficiency
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cervicobrachial syndrome
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cervicogenic headache
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Cognitive disorder
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Convulsion
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Dementia
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Dementia Alzheimer's type
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Dizziness
|
0.18%
7/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Drop attacks
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Dyskinesia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Embolic cerebral infarction
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Embolic stroke
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Epilepsy
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Essential tremor
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Facial palsy
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Global amnesia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Grand mal convulsion
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Guillain-Barre syndrome
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Haemorrhagic stroke
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Headache
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Hemianopia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Hemicephalalgia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Hemiplegia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Hydrocephalus
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Hypoglycaemic coma
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Ischaemic stroke
|
0.21%
8/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.18%
7/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Lacunar infarction
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Loss of consciousness
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Lumbar radiculopathy
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Migraine
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Miller Fisher syndrome
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Mononeuropathy
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Nerve root compression
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Parkinson's disease
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Parkinsonism
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Petit mal epilepsy
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Polyneuropathy
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Radicular syndrome
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Radiculopathy
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Sciatica
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Spinal claudication
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Spinal cord compression
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Subarachnoid haemorrhage
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Syncope
|
0.34%
13/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.36%
14/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Syncope vasovagal
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Tension headache
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.31%
12/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.36%
14/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Trigeminal neuralgia
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Vascular dementia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Vascular encephalopathy
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Vertebrobasilar insufficiency
|
0.21%
8/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Anxiety
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Confusional state
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Delirium
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Delusional disorder, unspecified type
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Depression
|
0.18%
7/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.23%
9/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Depressive symptom
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Dysthymic disorder
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Hypochondriasis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Insomnia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Mental disorder
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Panic attack
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Stress
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Acute prerenal failure
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Bladder prolapse
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Calculus ureteric
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Incontinence
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Nephritis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.15%
6/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Renal colic
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Renal cyst
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Renal disorder
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Renal failure
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Renal failure acute
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Tubulointerstitial nephritis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Ureteric stenosis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Adnexa uteri mass
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Breast cyst
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Breast dysplasia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Cervical dysplasia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Cervical polyp
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Colpocele
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Cystocele
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.13%
5/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Endometrial hyperplasia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Endometrial hypertrophy
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Female genital tract fistula
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Genital prolapse
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Metrorrhagia
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Ovarian cyst
|
0.15%
6/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Postmenopausal haemorrhage
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Rectocele
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Uterine haemorrhage
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Uterine polyp
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Uterine prolapse
|
0.21%
8/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.21%
8/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Uterine synechiae
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Uterovaginal prolapse
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Vaginal fistula
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Reproductive system and breast disorders
Vaginal prolapse
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Acute pulmonary oedema
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Asphyxia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.21%
8/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.23%
9/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Asthmatic crisis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis chronic
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchostenosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Choking
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.39%
15/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.36%
14/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.21%
8/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.28%
11/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Emphysema
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Hydrothorax
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Hyperventilation
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal cyst
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal oedema
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Mediastinal mass
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal polyps
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal septum deviation
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Nocturnal dyspnoea
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Obstructive airways disorder
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal oedema
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural disorder
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pleurisy
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.36%
14/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.28%
11/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary fibrosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary haemorrhage
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary hypertension
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary toxicity
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory arrest
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.18%
7/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Tracheobronchial dyskinesia
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Vocal cord cyst
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Vocal cord polyp
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Vocal cord thickening
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Angioedema
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Dermatitis allergic
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Pemphigus
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Pigmentation disorder
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Psoriasis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Purpura
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Scar
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Skin reaction
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.15%
6/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Toxic skin eruption
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Skin and subcutaneous tissue disorders
Vasculitic rash
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Social circumstances
Homicide
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Surgical and medical procedures
Carpal tunnel decompression
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Accelerated hypertension
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Aortic aneurysm
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Aortic aneurysm rupture
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Aortic dissection
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Aortic stenosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Arterial haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Arterial rupture
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Arterial stenosis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Arterial thrombosis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Arterial thrombosis limb
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Arteriosclerosis
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Arteriosclerosis obliterans
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Blood pressure fluctuation
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Deep vein thrombosis
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.23%
9/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Embolism
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Essential hypertension
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Femoral artery occlusion
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Haematoma
|
0.10%
4/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Hypertension
|
0.57%
22/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.49%
19/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Hypertensive crisis
|
0.15%
6/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Hypotension
|
0.13%
5/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Hypovolaemic shock
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Intermittent claudication
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Ischaemia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Orthostatic hypotension
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Peripheral embolism
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Peripheral ischaemia
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Peripheral vascular disorder
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Shock
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.05%
2/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Superior vena caval occlusion
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Temporal arteritis
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Thrombophlebitis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.08%
3/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Varicose vein
|
0.08%
3/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.10%
4/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Vascular insufficiency
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Vascular pseudoaneurysm
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Vasculitis
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Vena cava thrombosis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Venous stasis
|
0.03%
1/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Venous thrombosis limb
|
0.05%
2/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.00%
0/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Wound haemorrhage
|
0.00%
0/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
0.03%
1/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
Other adverse events
| Measure |
Placebo
n=3876 participants at risk
Placebo administered subcutaneously once every 6 months for 3 years.
|
Denosumab 60 mg Q6M
n=3886 participants at risk
Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
|
|---|---|---|
|
Eye disorders
Cataract
|
5.9%
230/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
5.6%
216/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Constipation
|
9.2%
356/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
9.0%
351/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Diarrhoea
|
6.0%
231/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
5.8%
224/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Gastrointestinal disorders
Dyspepsia
|
5.4%
209/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
4.5%
175/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Bronchitis
|
7.7%
298/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
7.6%
297/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Cystitis
|
5.8%
224/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
5.8%
225/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Influenza
|
8.6%
334/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
8.5%
331/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Nasopharyngitis
|
15.5%
600/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
14.5%
563/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Infections and infestations
Urinary tract infection
|
6.3%
246/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
6.0%
233/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Injury, poisoning and procedural complications
Fall
|
6.0%
233/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
4.9%
190/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
6.1%
236/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
7.2%
280/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
20.1%
778/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
20.0%
778/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
34.3%
1329/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
34.5%
1340/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
7.5%
289/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
7.6%
295/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
10.2%
397/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
9.9%
383/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
11.1%
430/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
11.6%
450/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Dizziness
|
5.5%
212/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
5.5%
213/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Nervous system disorders
Headache
|
6.6%
255/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
6.0%
234/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Psychiatric disorders
Depression
|
5.6%
217/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
5.3%
206/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
6.1%
238/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
5.8%
224/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
|
Vascular disorders
Hypertension
|
16.0%
619/3876 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
15.5%
603/3886 • 36 months
The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Seven participants who were randomized to placebo but received denosumab in error are summarized in the denosumab arm.
|
Additional Information
Study Director
Amgen Inc.
Phone: 866-572-6436
Results disclosure agreements
- Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
- Publication restrictions are in place
Restriction type: OTHER